115 related articles for article (PubMed ID: 37739104)
1. Optimized new Shengmai powder ameliorates myocardial fibrosis in rats with heart failure by inhibition of the MAPK signaling pathway.
Zhang Z; Song Y; Zhang X; Wang S; Jia Z; Wang L; Wang C; Wang X; Mao J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117210. PubMed ID: 37739104
[TBL] [Abstract][Full Text] [Related]
2. Optimized new Shengmai powder inhibits myocardial fibrosis in heart failure by regulating the rat sarcoma/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular regulated protein kinases signaling pathway.
Zeyu Z; Zhuangzhuang J; Yuwei S; Xuan Z; Ci W; Shuai W; Peipei Z; Qiuan R; Xianliang W; Jingyuan M
J Tradit Chin Med; 2024 Jun; 44(3):448-457. PubMed ID: 38767628
[TBL] [Abstract][Full Text] [Related]
3. Optimized New Shengmai Powder modulation of cAMP/Rap1A signaling pathway attenuates myocardial fibrosis in heart failure.
Zhang Z; Xu Z; Wang S; Jia Z; Zhou Z; Wang C; Lin S; Feng Y; Wang X; Mao J
Chin Med; 2024 Feb; 19(1):30. PubMed ID: 38402401
[TBL] [Abstract][Full Text] [Related]
4. Regulation of optimized new Shengmai powder on cardiomyocyte apoptosis and ferroptosis in ischemic heart failure rats: The mediating role of phosphatidylinositol-3-kinase/protein kinase B/tumor protein 53 signaling pathway.
Zhang ZY; Yang ZH; Wang S; Feng SL; Wang XL; Mao JY
J Ethnopharmacol; 2024 Aug; 330():118264. PubMed ID: 38692417
[TBL] [Abstract][Full Text] [Related]
5. Effect of optimized new Shengmai powder on exercise tolerance in rats with heart failure by regulating the ubiquitin-proteasome signaling pathway.
Wang S; Wang L; Gu S; Han Y; Li L; Jia Z; Gao N; Liu Y; Lin S; Hou Y; Wang X; Mao J
Front Cardiovasc Med; 2023; 10():1168341. PubMed ID: 37288261
[TBL] [Abstract][Full Text] [Related]
6. Dengzhan Shengmai capsule attenuates cardiac fibrosis in post-myocardial infarction rats by regulating LTBP2 and TGF-β1/Smad3 pathway.
Wang M; Wang M; Zhao J; Xu H; Xi Y; Yang H
Phytomedicine; 2023 Jul; 116():154849. PubMed ID: 37163903
[TBL] [Abstract][Full Text] [Related]
7. YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway.
Pang LZ; Ju AC; Zheng XJ; Li F; Song YF; Zhao Y; Gu YF; Chen FL; Liu CH; Qi J; Gao Z; Kou JP; Yu BY
J Ethnopharmacol; 2017 Apr; 202():67-77. PubMed ID: 28237302
[TBL] [Abstract][Full Text] [Related]
8. Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure.
Zhang Z; Yang Z; Wang S; Wang X; Mao J
Biomed Pharmacother; 2024 Apr; 173():116413. PubMed ID: 38461687
[TBL] [Abstract][Full Text] [Related]
9. Luhong formula inhibits myocardial fibrosis in a paracrine manner by activating the gp130/JAK2/STAT3 pathway in cardiomyocytes.
Qu H; Wang Y; Wang Y; Yang T; Feng Z; Qu Y; Zhou H
J Ethnopharmacol; 2017 Apr; 202():28-37. PubMed ID: 28115285
[TBL] [Abstract][Full Text] [Related]
10. Effects and mechanism of Compound Qidan Formula on rats with HFpEF induced by hypertension and diabetes mellitus based on Ang Ⅱ/TGF-β1/Smads signaling pathway.
Yuan P; Liu J; Xiong S; Yang L; Guan J; Dong G; Shi D
J Ethnopharmacol; 2023 Sep; 313():116558. PubMed ID: 37116729
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of tanshinone II A inhibiting myocardial remodeling by Galectin-3].
Zhang M; Cheng K; Yu L; Wu W; Wang Y; Chen Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jun; 34(6):640-645. PubMed ID: 35924522
[TBL] [Abstract][Full Text] [Related]
12. The application of proteomics and metabolomics to reveal the molecular mechanism of Nutmeg-5 in ameliorating cardiac fibrosis following myocardial infarction.
Yan T; Zhu X; Zhang X; Jia X; Liu J; Wang X; Xiao Y; Xiao Z; Liu T; Dong Y
Phytomedicine; 2022 Oct; 105():154382. PubMed ID: 35963196
[TBL] [Abstract][Full Text] [Related]
13. Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure.
Zhao Y; Jiang Y; Chen Y; Zhang F; Zhang X; Zhu L; Yao X
J Ethnopharmacol; 2020 Feb; 248():112050. PubMed ID: 31265887
[TBL] [Abstract][Full Text] [Related]
14. Injection of YiQiFuMai powder protects against heart failure via inhibiting p38 and ERK1/2 MAPKs activation.
Nie Y; Zhang Y; Li Z; Wan M; Li D
Pharm Biol; 2022 Dec; 60(1):570-578. PubMed ID: 35244521
[TBL] [Abstract][Full Text] [Related]
15. Qishenyiqi Dropping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation.
Wang J; Lu L; Wang Y; Wu Y; Han J; Wang W; Li C; Tu P
J Ethnopharmacol; 2015 Dec; 176():375-84. PubMed ID: 26590099
[TBL] [Abstract][Full Text] [Related]
16. Ling-Gui-Qi-Hua formula alleviates left ventricular myocardial fibrosis in rats with heart failure with preserved ejection fraction by blocking the transforming growth factor-β1 /Smads signaling pathway.
Shi Y; Liu C; Xiong S; Yang L; Yang C; Qiao W; Liu Y; Liu S; Liu J; Dong G
J Ethnopharmacol; 2023 Dec; 317():116849. PubMed ID: 37385575
[TBL] [Abstract][Full Text] [Related]
17. Qishen granule attenuates cardiac fibrosis by regulating TGF-β /Smad3 and GSK-3β pathway.
Zeng Z; Wang Q; Yang X; Ren Y; Jiao S; Zhu Q; Guo D; Xia K; Wang Y; Li C; Wang W
Phytomedicine; 2019 Sep; 62():152949. PubMed ID: 31102891
[TBL] [Abstract][Full Text] [Related]
18. Ghrelin suppresses cardiac fibrosis of post-myocardial infarction heart failure rats by adjusting the activin A-follistatin imbalance.
Yang C; Liu J; Liu K; Du B; Shi K; Ding M; Li B; Yang P
Peptides; 2018 Jan; 99():27-35. PubMed ID: 29113826
[TBL] [Abstract][Full Text] [Related]
19. Butorphanol protects on myocardial ischemia/reperfusion injury in rats through MAPK signaling pathway.
Wang H; Wang JL; Ren HW; He WF; Sun M
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10541-10548. PubMed ID: 31841210
[TBL] [Abstract][Full Text] [Related]
20. Shengmai Yin formula exerts cardioprotective effects on rats with chronic heart failure via regulating Linoleic Acid metabolism.
Wang S; Gan J; Li J; Wang Y; Zhang J; Song L; Yang Z; Guo M; Jiang X
Prostaglandins Other Lipid Mediat; 2022 Feb; 158():106608. PubMed ID: 34958945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
